Abbott Laboratories Q2 2026 Results and Guidance Update

Abbott Laboratories reported strong second-quarter 2026 results, with total reported sales increasing by 13.0% to $12.593 billion and comparable sales growth at 4.8%. The company announced a GAAP diluted EPS of $0.53 and an adjusted diluted EPS of $1.31. Abbott raised its full-year 2026 adjusted diluted EPS guidance to a range of $5.45 to $5.60, while reaffirming its comparable sales growth guidance of 6.5% to 7.5%. Key business segments showed varied performance: Nutrition sales decreased slightly, Diagnostics saw significant reported sales growth driven by the Exact Sciences acquisition, Established Pharmaceuticals experienced robust growth, and Medical Devices delivered a solid 9.0% reported sales increase. The company also highlighted advancements in its product pipeline, including regulatory submissions and clinical trial progress for various medical devices. Abbott returned $2.1 billion to shareholders in the quarter through dividends and share repurchases, underscoring its commitment to shareholder returns.